

**Table 2.11. Cohort studies of combined estrogen–progestogen contraceptives and colorectal cancer**

Reference	Country and study	Population/person years (follow-up); No. of cases/deaths	Relative risk (95% CI) (ever versus never users)			Comments
			Colorectal	Colon	Rectum	
Chute et al. (1991); Martínez et al. (1997)	USA Nurses' Health Study	89 448 (12 years); 501 cases	0.84 (0.69–1.02)	0.64 (0.40–1.02)	0.76 (0.49–1.18)	Adjusted for age, body mass index, exercise, family history of cancer, aspirin, alcohol, meat intake, menstrual factors; significant inverse trend with duration of use
Bostick et al. (1994)	Iowa State, USA	35 215 (4 years); 212 cases	–	1.0 (0.7–1.4)	–	Adjusted for age, height, parity, caloric intake, vitamin intake
Troisi et al. (1997)	USA BCDDP	57 528 (10 years); 95 cases	1.0 (0.7–1.4)	–	–	Adjusted for age only; adjustment for education, body mass index did not alter relative risk; no significant effect with duration of use.
Hannaford et al. (2007)	United Kingdom RCGP OCS	46 000 (36 years); 323 cases,	0.72 (0.58–0.90)	–	–	Adjusted for age, social class, smoking, parity
van Wayenburg et al. (2000)	Netherlands DOM Study	10 671 (18 years); 95 deaths	0.68 (0.21–2.21)	–	–	Adjusted for age at entry, age at first birth, smoking, type of menopause, socioeconomic status, body mass index
Vessey and Painter (2006)	United Kingdom OPFA Study	17 032 (33 years); 131 cases	0.8 (0.6–1.2)	–	–	Relative risk of death for use < 24 months versus never use; no trend with duration of use; adjusted for age, parity, social class, smoking
Rosenblatt et al. (2008)	Shanghai, China	267 400 (10 years); 655 colon cancer cases 368 rectal cancer cases	–	1.09 (0.86–1.37)	1.31 (0.98–1.75)	No trend with duration of use; adjustment for age, parity

**Table 2.11. Cohort studies of combined estrogen–progestogen oral contraceptives and colorectal cancer**

Reference	Country and study	Population/person years (follow-up); No. of cases/deaths	Relative risk (95% CI) (ever versus never users)			Comments
			Colorectal	Colon	Rectum	
Lin et al. (2007)	USA, Woman's Health Study	39 680 (11 years) 680 cases	0.67 (0.50–0.89)	0.73 (0.52–1.01)	0.52 (0.28–0.96)	No trend in risk with duration of use.
Kabat et al. (2007a)	Canada, Canadian National Breast Screening Study	89 835 (16.4 years) 1 142 cases	0.83 (0.73–0.94)	0.81 (0.70–0.94)	0.85 (0.67–1.03)	No trends in risk with duration of use.

BCDDP, Breast Cancer Detection Demonstration Project; CI, confidence interval; DOM, Diagnostisch Onderzoek Mammacarcinoom; OFPA, Oxford Family Planning Association; RCGP OCS, Royal College of General Practitioners Oral Contraceptive Study